Drug intelligence / Profile preview

CTN 008

Development stage: Preclinical
Lead developer: Centenaire Biosciences
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

CTN 008 is an Fc-engineered monoclonal antibody that targets CD33. It is being developed by Centenaire Biosciences for the treatment of acute myeloid leukemia. The drug's mechanism involves binding to the CD33 antigen, which is commonly expressed on leukemic cells in acute myeloid leukemia, potentially leading to targeted immune-mediated destruction of these cancerous cells[1].

Targets

CD33 (Myeloid cell surface antigen CD33)

Beyond the preview

Go deeper on CTN 008.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTN 008.

Explore the full profile